Literature DB >> 17542458

Project ECHO: linking university specialists with rural and prison-based clinicians to improve care for people with chronic hepatitis C in New Mexico.

Sanjeev Arora1, Karla Thornton, Steven M Jenkusky, Brooke Parish, Joseph V Scaletti.   

Abstract

Project Extension for Community Healthcare Outcomes (Project ECHO) is a telemedicine and distance-learning program designed to improve access to quality health care for New Mexicans with hepatitis C. Project ECHO links health-care providers from rural clinics, the Indian Health Service, and prisons with specialists at the University of New Mexico. At weekly clinics, partners present and discuss patients with hepatitis C with specialists. Partners can receive continuing education credits for participating. Since June 2003, 173 hepatitis C clinics have been conducted with 1,843 case presentations. Partners have received 390 hours of training and 2,997 hours of continuing education credits. And in 2006, the State Legislature approved $1.5 million in annual funding for the project. Project ECHO has increased access to state-of-the art hepatitis C virus care for patients living in rural areas or prisons. Because of its success with hepatitis C, this project is being expanded to other chronic medical conditions.

Entities:  

Mesh:

Year:  2007        PMID: 17542458      PMCID: PMC1831800          DOI: 10.1177/00333549071220S214

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  8 in total

1.  Sexually transmitted diseases treatment guidelines, 2006.

Authors:  Kimberly A Workowski; Stuart M Berman
Journal:  MMWR Recomm Rep       Date:  2006-08-04

2.  Academic health center management of chronic diseases through knowledge networks: Project ECHO.

Authors:  Sanjeev Arora; Cynthia M A Geppert; Summers Kalishman; Denise Dion; Frank Pullara; Barbara Bjeletich; Gary Simpson; Dale C Alverson; Lori B Moore; Dave Kuhl; Joseph V Scaletti
Journal:  Acad Med       Date:  2007-02       Impact factor: 6.893

3.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

4.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

5.  Establishing a viral hepatitis prevention and control program: Florida's experience.

Authors:  Linda M Baldy; Cheryl Urbas; Jennie L Harris; T Stephen Jones; Philip E Reichert
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

6.  Integrating viral hepatitis prevention services into an urban STD clinic: Denver, Colorado.

Authors:  Julie Subiadur; Jennie L Harris; Cornelis A Rietmeijer
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

7.  Integrating viral hepatitis prevention into STD clinics in Illinois (excluding Chicago), 1999-2005.

Authors:  Richard Zimmerman; Carol Finley; Charlie Rabins; Karen McMahon
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

8.  Texas statewide hepatitis C counseling and testing, 2000-2005.

Authors:  Gary Heseltine; Jenny McFarlane
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

  8 in total
  48 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  The Patient-Centered Medical Neighborhood and Diabetes Care.

Authors:  Christin Spatz; Robert Gabbay
Journal:  Diabetes Spectr       Date:  2014-05

3.  Integrating viral hepatitis prevention into public health programs serving people at high risk for infection: good public health.

Authors:  Joanna Buffington; T Stephen Jones
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

4.  Managing chronic hepatitis C in primary-care settings: more than antiviral therapy.

Authors:  Barry Zevin
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

5.  Integrating the Lived Experience Conditions and Care in the ECHO Model.

Authors:  Tracy Greever-Rice; Lea Brandt; Melissa Warne-Griggs; Kimberly Hoffman
Journal:  Mo Med       Date:  2020 May-Jun

6.  Teleconsultation for clinicians who provide human immunodeficiency virus care: experience of the national HIV telephone consultation service.

Authors:  Jessica F Waldura; Sarah Neff; Ronald H Goldschmidt
Journal:  Telemed J E Health       Date:  2011-05-25       Impact factor: 3.536

Review 7.  The Current and Future Use of Telemedicine in Infectious Diseases Practice.

Authors:  Caitlin E Coombes; Megan E Gregory
Journal:  Curr Infect Dis Rep       Date:  2019-10-19       Impact factor: 3.725

8.  A Family Medicine Health Technology Strategy for Achieving the Triple Aim for US Health Care.

Authors:  Robert L Phillips; Andrew W Bazemore; Jennifer E DeVoe; Thomas J Weida; Alex H Krist; Michael F Dulin; Frances E Biagioli
Journal:  Fam Med       Date:  2015-09       Impact factor: 1.756

9.  Epidemiology of Infectious Disease-Related Death After Release from Prison, Washington State, United States, and Queensland, Australia: A Cohort Study.

Authors:  Ingrid A Binswanger; Patrick J Blatchford; Simon J Forsyth; Marc F Stern; Stuart A Kinner
Journal:  Public Health Rep       Date:  2016 Jul-Aug       Impact factor: 2.792

Review 10.  Personalized Technologies in Chronic Gastrointestinal Disorders: Self-monitoring and Remote Sensor Technologies.

Authors:  Muhammad Safwan Riaz; Ashish Atreja
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-14       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.